An observational study in Sacro Iliac Joint Pain, Sacro-iliac Joints and Sacroiliac Disorder, sponsored by SI-BONE, Inc.. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by SI-BONE, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate outcomes in patients treated with iFuse INTRA Ti for chronic SI joint pain.
PIERCE is a prospective, multicenter, post-market observational study evaluating the safety, performance, and efficacy of iFuse INTRA Ti.
277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.
This study's planned enrollment of 120 is close to the median of 114 across 50 observational studies indexed under Arthralgia.
Browse Arthralgia studies →SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with sacroiliac joint (SIJ) dysfunction due to degenerative sacroiliitis or sacroiliac joint disruption for at least 6 months refractory to non-surgical care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with sacroiliac joint (SIJ) dysfunction due to various causes refractory to non-surgical management.
Device: iFuse INTRA Ti Implant System
FDA-cleared implant used for fusion of the sacroiliac joint (SIJ) for SIJ dysfunction, that is a direct result of SIJ disruption and degenerative sacroiliitis.
Composite endpoint of safety and performance
The participant is considered a success if all the following criteria are met: * A ≥ 2 point improvement from baseline in SIJ pain on the target side. * Absence of device-related SAE. * Absence of SSI at index procedure.
Time frame: 6 months.
Proportion of Participants with a Serious Adverse Event (SAE)
Proportion of participants with a serious adverse event classified as probably or definitely related to the study device or procedure
Time frame: 24 months
Proportion of Participants with ≥1 Subsequent Surgical Intervention(s) (SSI)
Proportion of participants undergoing one or more SSI related to the index procedure.
Time frame: 24 months
Proportion of Treated Sides with Radiographic Evidence of Loosening
Proportion of treated sides showing signs of loosening of INTRA Ti, as evidenced by both radiolucent areas around implant plus bony reaction ("rind") near implant.
Time frame: 24 months
Proportion of Implants with Radiographic Evidence of Device Migration.
Proportion of INTRA Ti implants that show evidence of device migration.
Time frame: 24 months
Proportion of Implants with Radiographic Evidence of Device Breakage.
Proportion of INTRA Ti implants that show breakage.
Time frame: 24 months
Proportion of Participants with Radiographic Evidence of Fusion
Bony apposition to the implant at 12 months as evaluated by pelvic CT
Time frame: 24 months
No study locations are listed for this record.
Plan to share: No — There are currently no plans to share but IPD may be shared with qualified researchers upon reasonable request, subject to sponsor approval and data use agreements.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.
Of 21 observational studies under Arthralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 18 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2026 → Dec 2026, primary completion Mar 2028 → Jun 2028 and completion Sep 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SI-BONE, Inc.